ERCC1基因19007C/T多态性与上皮性卵巢癌铂类联合化疗反应关系的Meta分析

摘要

目的：探讨ERCC1基因19007C/T多态性与上皮性卵巢癌铂类联合化疗反应的关系。方法全面检索Pubmed、HuGENet及万方数据库，按照纳入、排除标准选取文献并提取相关数据进行Meta分析，采用Stata 11.0软件分析ERCC1不同基因型与化疗反应的关系。结果纳入7篇文献共711例患者，ERCC1基因19007C/T多态性与上皮性卵巢癌铂类联合化疗反应性之间的差异无统计学意义（P>0.05）。进一步对每种模型按照种族、标本来源、是否哈温平衡及基因型检测方法进行分层分析，发现其结果亦均无统计学意义（P>0.05）。结论未发现ERCC119007C/T基因型与上皮性卵巢癌患者对铂类联合化疗敏感性之间的联系，未来需要设计良好的大样本试验以进一步研究。%Objective To explore the relationship between the 19007C/T polymorphism in the excision repair cross-complementation group 1(ERCC1)gene and response of patients with epithelial ovarian cancer to platinum-based combination chemotherapy. Methods Pubmed, HuGENet and Wanfang databases were systematically searched, and Stata 11.0 meta-analysis was used to explore relationships of different genotypes of the 19007C/T polymorphism and chemotherapy response. Results 7 eligible studies involving 711 patients were retrieved. No significant associations were found in meta-analyses of ERCC1 gene 19007C/T polymorphism and chemosensitivity to Cisplatin.Race,Specimen source,whether the hardy Weinberg equilibrium and gene detection method were stratified analysis in each model,but there was no statistical significance. Conclusion This meta-analysis did not identify any significant relationships between the ERCC1 19007C/T polymorphism and response of patients with epithelial ovarian cancer to platinum-based combination chemotherapy. Large,well-designed studies are needed to verify these findings.